Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Engages Maxim
Group LLC to Evaluate Strategic Opportunities
(Investorideas.com Newswire) Investorideas.com,
a leading investment platform for retail investors reports breaking Medical
Tech Stock news for Aethlon Medical, Inc. (Nasdaq: AEMD),
a medical therapeutic company focused on developing products to treat
cancer and life-threatening infectious diseases.
Aethlon Medical, Inc. (Nasdaq: AEMD) today announced that it is evaluating a range of strategic opportunities
and has engaged Maxim Group LLC (“Maxim”) to act as the Company’s exclusive
financial advisor in connection with this process.
The Company engaged Maxim following preliminary
inbound interest regarding potential strategic opportunities. Maxim will assist the Company in reviewing a
range of potential transactions, including partnerships, mergers, acquisitions
or other opportunities involving the Company.
Paid News Dissemination
of behalf of AEMD
Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/03121-aethlon-aemd-maxim-strategic-opportunities.asp
James Frakes, Chief Executive Officer and Chief
Financial Officer of Aethlon stated, “The Company continues to execute its
development activities, having completed the second cohort of our Australian
oncology trial. Safety data from that cohort will be submitted to
the independent Data Safety Monitoring Board for review. At the
same time, we are evaluating strategic alternatives with the assistance of
Maxim as part of our ongoing efforts to assess opportunities available to the
Company and its shareholders.”
The Company has not established a definitive
timeline for this evaluation and can provide no assurance that any transaction
will result from this process. The
Company will pursue only those opportunities that the Board believes are
appropriate for the Company and its shareholders.
About Maxim
Group LLC
Founded in 2002, Maxim Group is a leading
full-service investment bank, securities and wealth management firm
headquartered in Midtown Manhattan providing a comprehensive array of financial
services including investment banking, global institutional sales, equity
research, fixed income and derivative sales & trading, merchant capital, private
wealth management, and prime brokerage services to a diverse range of corporate
clients, institutional investors and high-net-worth individuals. Maxim Group is
a registered broker-dealer with the U.S. Securities and Exchange Commission and
the Municipal Securities Rulemaking Board (MSRB). To learn more about Maxim
Group, visit www.maximgrp.com.
About Aethlon Medical, Inc.
Aethlon Medical,
Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in
San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet
needs in oncology and infectious disease, using a novel platform designed to
selectively remove circulation pathogenic targets from biologic fluids.
For more information, visit www.AethlonMedical.com
and follow the Company on LinkedIn.
Forward-Looking
Statements
This press
release contains forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934 that involve risks and uncertainties. Statements containing words such as
"may," "believe," "anticipate,"
"expect," "intend," "plan," "project,"
"will," "projections," "estimate,"
"potentially" or similar expressions constitute forward-looking
statements. Forward-looking
statements in this release include, without limitation, statements regarding
the Company’s engagement of Maxim Group LLC, the exploration or identification
of potential strategic merger and acquisition alternatives, the possibility,
timing or structure of any transaction, and the potential benefits of any such
transaction. Such forward-looking statements are subject to significant risks
and uncertainties, and actual results may differ materially from the results
anticipated in the forward-looking statements. There can be no assurance that
the Company’s engagement of a financial advisor will result in the
identification or consummation of any transaction. The Company may determine to
suspend or terminate the exploration of strategic alternatives at any time, and
no timetable has been set for completion of this process. Risks and
uncertainties that could cause actual results to differ materially from those
expressed or implied by these forward-looking statements include, without
limitation: the Company’s ability to identify suitable transaction partners;
the risk that any discussions with third parties do not result in a definitive
agreement; the risk that a transaction, if agreed upon, is not consummated;
potential disruption to the Company’s business as a result of the announcement
or pendency of a strategic review process; the diversion of management’s time
and attention; the Company’s ability to maintain compliance with Nasdaq listing
standards; the Company’s ability to raise additional capital; and other risks
and uncertainties described under the caption “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended March 31, 2025, and in its other
filings with the Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which they were
made. Except as may be required by law, the Company does not intend, nor does
it undertake any duty, to update this information to reflect future events or
circumstances or disclose developments.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall it constitute an
offer, solicitation or sale in any jurisdiction in which such offer,
solicitation or sale would be unlawful. Any securities that may be offered in
connection with a potential transaction would be offered only pursuant to an
effective registration statement or in reliance upon an applicable exemption
from registration requirements.
Company Contacts:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
Aethlon Medical Inc. (Nasdaq:AEMD) is
a featured biotech stock on Investorideas.com
More info on AEMD at
Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/
Get News Alerts on Aethlon Medical
Disclaimer/Disclosure: Athelon Medical, Inc. (AEMD) is
a paid featured medical tech stock on Investor
ideas More disclosure: Investorideas.com is a digital
publisher of third party sourced news, articles and equity research as well as
creates original content, including video, interviews and articles. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investing involves risk and possible losses. This site is currently compensated
for news publication and distribution, social media and marketing, content
creation and more. More disclosure: Contact management and IR of each
company directly regarding specific questions.
About Investorideas.com – Where you
find the best investing ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock
news to top-rated investing podcasts, we cover it all
Get more biotech and medical tech news, articles, podcasts and stock directories
Follow us on X @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Sign
up for free stock news alerts at Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
No comments:
Post a Comment